PHIBRO ANIMAL HEALTH CORP — Form 8-K
Filed August 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
FY2026 net sales reached $1,518.1M (+17% YoY, +$221.9M); adjusted EBITDA $255.0M (+39% YoY, +$71.3M); diluted EPS $2.43 (+$1.24). Company announced planned closure of Chicago Heights manufacturing facility (100 employees affected, production ceases summer 2027) following MFA acquisition integration review. FY2027 guidance: $1.55–1.60B sales (+4%), $258–268M adjusted EBITDA (+3%), assumes minimal virginiamycin sales in Brazil pending regulatory approval.
Why this rating
Strong earnings growth and margin expansion offset by meaningful plant closure (~$100M asset base est.) and modest guidance slowdown relative to FY2026. Mixed near-term signal.
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.